Joe Biden’s global corporation tax deal: A prediction on what’s next
Why have the nations of the world agreed to a new minimum corporation tax rate? And what happens to so-called "Google taxes" now?
Business & Regulation
Regulatory roundup: BMS’s T lymphocyte immunotherapy tripped by lung cancer trial termination
Sanofi’s pemphigus asset, Artios solid tumor trial among recent events reviewed by GlobalData’s Investigative News...
Regulatory roundup: Ology, MaxCyte make moves in women’s cancer with divergent approval chances
GlobalData’s Investigative News team reviews recent events that impacted a drug’s path to regulatory approval.
Multiple myeloma: first bispecific mAb to secure r/r approval will have biggest market bite
Market latecomers will likely struggle to demonstrate value-added edge so early strategic decisions are critical.
Regulatory roundup: Akeso’s bispecific antibody moves closer to approval in China
GlobalData’s Investigative News team reviews recent events that impacted a drug’s path to regulatory approval.
Novavax Covid-19 vaccine booster: safety and manufacturing questions remain
Novavax’s Covid-19 vaccine could find its niche as a booster shot, but questions linger around its safety and production.
Regulatory roundup: Alexion ALS drug sees approval prospects plummet
GlobalData’s Investigative News team reviews recent events that impacted a drug’s path to regulatory approval.
Gilead’s lenacapavir: HIV prospects strongest in long-acting combos with Merck’s islatravir
Gilead’s lenacapavir will find its strongest niche as a long-acting HIV combination treatment, experts said.
Akebia and GSK will grapple with heightened scrutiny of HIF PHIs after roxadustat concerns
The firms may struggle to convince regulators that their HIF PHIs don't share roxadustat’s safety concerns in CKD.
Regulatory roundup: Servier, Pfizer and Debiopharm gather gains with oncology trial updates; Karyopharm poses a loss
GlobalData’s Investigative News team reviews oncology and nononcological events that impacted drugs’ paths to approval.
Race to develop mRNA flu vaccines will contend with a longer review than Covid-19
Covid-19 jumpstarted mRNA vaccine timelines for other infectious diseases, but approvals for these will likely be slower.
